CClinicalTrials.gg
RecruitingNCT05241119Updated Feb 15, 2022

Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy

An interventional study of SLNB and pALND in Breast Cancer, sponsored by Shengjing Hospital. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-15.

Sponsored by Shengjing Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 4 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

For patients with early breast cancer with negative axillary lymph nodes, sentinel lymph node biopsy (SLNB) can largely avoid complications such as upper limb lymphoedema caused by axillary lymph node dissection (ALND). Locally advanced breast cancer requires neoadjuvant chemotherapy (NAC), based on the breast cancer treatment guidelines. In addition to shrinking the primary breast lesion, NAC can reduce the stage for axillary positive lymph nodes. Therefore, in recent years clinicians have been considering SLNB for patients whose axillary lymph nodes have turned negative after NAC. After verification by the clinical trials, the current NCCN guidelines recommend that patients with T1-3N0-1 undergo SLNB after NAC, however, the false negative rate (FNR) of conventional SLNB after NAC is as high as 14%, which potentially leads to underestimation of the risk for recurrence and metastasis, insufficient adjuvant therapy, eventually affects long-term survival. Thus, how to accurately assess and treat axillary lymph nodes after NAC remains an urgent clinical question to be answered.

In recent years, a method using a metal clip to label positive lymph node before NAC has emerged in order to reduce the FNR of SLNB after NAC. Its principle is to trace the metastasized lymph node, so that the lymph node can be accurately found in the surgery, even if the lymph node is not blue-stained at the time. Apparently, this method is more suitable for small number of nodes, and inappropriate for more than two metastasized nodes.

The diameter of manocarbon particles (150nm) is between that of lymphatic capillaries (120-500nm) and capillaries (20-50 nm). With the unique macrophage phagocytosis, nanocarbon particles can remain in the lymphatic system for a long time. Using nanocarbon to label positive lymph nodes before NAC, our pilot study explored the regression of axillary lymph nodes after NAC. We found that, except for a small number of drug-resistant patients, the regression of positive lymph nodes after NAC followed a pattern of from the superior to the inferior, and from the medial to the lateral. We also found that, the worse the efficacy of NAC, the fewer black-stained nodes after NAC, suggesting long-term tracing of positive axillary lymph nodes by nanocarbon particles can guide precise treatment of axillary lymph nodes after NAC. These findings are integrated with our previous research project which investigated the spatial distribution of positive axillary lymph nodes with the intercostals brachial nerve (ICBN) as the boundary. It is proposed that low lymph node dissection below ICBN (pALND) may be a safe and efficient method reducing lymphoedema in patients with negative nodes after NAC. Prone position CT scan combined with clinical palpation of axillary lymph nodes can comprehensively evaluate axillary conditions in patients with breast cancer before surgery, and determine node metastasis accurately, and make correct clinical plans.

Read the detailed description

A total of 100 patients who are first diagnosed with breast cancer (stage N2 or N3) at the Liaoning Oncology Hospital will be recruited. Inclusive criteria: 1) Invasive breast cancer confirmed by biopsy and histology; 2) based on prone CT scan and Doppler ultrasound, axillary stage cN2-3; 3) agree and meet the requirements for NAC; 4) meet surgical requirements and agree to undergo surgery after NAC; 5) the regime of NAC follows the NCCN recommendations. Exclusive criteria: previous history of breast cancer or other malignant tumors. Period of investigation: 2 years.

After informed consent is obtained, under ultrasound guidance, the metastatic lymph node with the largest diameter (> 1 cm) is selected and injected under the cortex with 0.3 ml of nanocarbon. If the cortex and medulla are difficult to distinguish, inject on the surface of the node. Patients with efficacy for NAC should complete the scheduled cycles of NAC. Alteration of NAC regime is allowed for patients whose initial NAC is inefficacious, as guided by the physicians.

Surgery is performed within four weeks after completion of the last cycle of NAC. Axillary lymph nodes are assessed using CT scan. For patients with neoadjuvant efficacy of CR and PR, axillary surgery is performed under fluorescent tracing. SLNB is performed for patients with extensive black staining nodes. Standard ALND is performed if SLN is positive. For patients with less than three black-stained nodes, pALND will be performed rather than SLNB. If axilary lynph nodes under the ICBN are proved positive by frozen histology, ALND is then performed. For those with neoadjuvant efficacy of SD or PD, pALND will be performed if there are extensive black-stained nodes. Standard ALND will be performed if lymph nodes are positive as assessed by intraoperative frozen histology. ALND will be performed if the number of black-stained nodes is less than 3.

All the clinical information and imaging data will be securely preserved, including surgical procedure, black-stained and metastasized lymph nodes. Short-term observatory measures include axillary drainage (quantity, extubation time) and upper limb lymphatic drainage (changes in arm circumference 10cm above and below the elbow pre and post surgery. Long-term observatory measures include axillary recurrence rate and lymphoedema 3-5 years after surgery.

02

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer, neoadjuvant chemotherapy, lymph nodes, nanocarbon
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 100 is above the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Shengjing Hospital is the lead sponsor of 124 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • invasive breast cancer confirmed by biopsy and histology;
  • based on prone CT scan and Doppler ultrasound, axillary stage cN2-3;
  • agree and meet the requirements for NAC;
  • meet surgical requirements and agree to undergo surgery after NAC;
  • the regime of NAC follows the NCCN recommendations.

Exclusion criteria

Exclusion Criteria:

  • previous history of breast cancer or other malignant tumors.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    SLNB Group

    undergo fluorescence SLNB

    Procedure: SLNB

  • Experimental
    pALND Group

    undergo low axillary lymph node dissection with ICBN as the boundary

    Procedure: pALND

  • Experimental
    ALND Group

    undergo ALND

    Procedure: ALND

Interventions

  • ProcedureSLNB

    undergo fluorescence SLNB.

  • ProcedurepALND

    undergo low axillary lymph node dissection with ICBN as the boundary

  • ProcedureALND

    undergo ALND

06

What researchers measure

Primary outcomes

  1. post-surgery pathology concordance rate

    post-surgery pathology concordance rate:investigate if the false negative rates in SLNB and ALND groups are consistent with post-surgery pathological results.

    Time frame: up to 3 weeks

Secondary outcomes

  1. Axillary drainage

    daily quantity of drainage for patients

    Time frame: up to 3 weeks

  2. Upper limb lymphatic drainage

    Upper limb lymphatic drainage:investigate the changes in aim circumference 10 cm above and below the elbow two weeks, six months, 12 months after surgery, among SLNB, pALND and ALND groups.

    Time frame: up to 5 years

  3. Axillary recurrence rate 3-5 years after surgery

    Axillary recurrence rate 3-5 years after surgery:the time between the start of treatment and the first diagnosis of axillary recurrene.

    Time frame: up to 5 years

  4. Upper limb lymphoedema

    Clinical judgment is mainly by asking the patient's subjective feelings or physical examination and performing a multi-segment ratio for measurement. It is generally determined that the peripheral diameter of the upper limb on the affected side is longer than the circumference of the contralateral upper limb\< 3 cm is mild edema, 3 to 5 cm is moderate edema, and the \> 5 cm is severe edema.

    Time frame: up to 5 years

07

Study locations

2 of 2 sites recruiting
  • Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
    Recruiting
  • Jianyi Li
    Shenyang, Liaoning 110042, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05241119
Lead sponsor
Shengjing Hospital
Responsible party
Jianyi Li (Principal Investigator, Shengjing Hospital) — Principal investigator
First posted
Feb 15, 2022
Start date
Nov 1, 2021
Primary completion
Oct 31, 2023 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Feb 15, 2022

Study contacts

Jianyi Li, Master
Contact
sjbreast@yeah.net
8618940257177
Jianyi Jianyi, Master
principal investigator · Cancer Hospital of China Medical University, Liaoning Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion